Commodore Capital LP 13D and 13G filings for Spyre Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 4:05 pm Purchase | 2024-09-30 | 13G | Spyre Therapeutics, Inc. SYRE | Commodore Capital LP | 1,988,084 3.900% | 54,000 (+2.79%) | Filing |
| 2024-02-14 4:05 pm Purchase | 2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | Commodore Capital LP | 1,934,084 5.400% | 100,000 (+5.45%) | Filing |
| 2023-12-01 4:15 pm Purchase | 2023-11-24 | 13G | Spyre Therapeutics, Inc. SYRE | Commodore Capital LP | 1,834,084 6.100% | 1,834,084 (New Position) | Filing |